CSPC Innovation Pharmaceutical: The explanation of this transaction is in compliance with Article 18 and 21 of the Measures for the Continuous Supervision of Listed Companies on the Growth Enterprise Market (Trial), as well as Article 8 of the Shenzhen Stock Exchange's Rules for the Review of Major Asset Restructurings of Listed Companies.

SZSI · Jul 24

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

新诺威：关于本次交易符合《创业板上市公司持续监管办法（试行）》第十八条、第二十一条以及《深圳证券交易所上市公司重大资产重组审核规则》第八条规定的说明

Risk Disclaimer

Statement